Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: A pilot study

Figures & data

Table I.   Characteristics before treatment. Results are expressed as median and quartile range.

Parameters	Group 1 (n=10) T gel	Group 2 (n=20) TU	p
Age	43.5 (39.0–54.0)	53.5 (43.5–66.0)	0.3
AMS score	40.0 (34.0–44.0)	39.5 (35.0–44.0)	0.86
IPSS score	12.0 (9.0–19.0)	11 (8–18.5)	0.66
Irritative symptoms (questions 2,4,7)	7.5 (6.0;11.0)	5.5 (2.0;10.0)	0.1
Obstructive symptoms (questions 1,3,5,6)	4.5 (3.0;7.0)	5.5 (5.0;7.5)	0.17
Nocturia	2.5 (1.0;4.0)	2.0 (1.0;3.0)	0.54
IIEF-5 score	12.0 (2.0–15.0)	14.5 (6.0–18.0)	0.3
Total testosterone level (nmol/L)	6.65 (5.6–9.4)	8.3 (5.7–10.8)	0.5
Calculated free testosterone level (pmol/L)	139.5 (115.0–161.0)	149.5 (115.5–177.0)	0.57
SHBG (nmol/L)	30.2 (25.6–40.9)	34.3 (27.05–53.2)	0.32
total PSA (pg/mL)	0.85 (0.5–1.5)	0.65 (0.4–1.21)	0.4

Table II.   Results of treatment in group 1 treated with Tgel during 26 weeks of treatment. Results are expressed as median and quartile range.

	Before treatment	16 weeks	26 weeks	p
AMS score	39.5 (35.0–44.0)	30.5 (22.0–36.0)	23.5 (20.0–25.5)	<0.00001
IPSS score	11 (8–16.5)	6.0 (3.0–7.5)	4.0 (1.5–7.0)	<0.00001
Irritative symptoms (questions 2,4,7)	5.5 (2.0;10.0)	4.0 (2.0;5.0)	2.0 (1.0;4.0)	<0.001
Obstructive symptoms (questions 1,3,5,6)	5.5 (5.0;7.5)	2.0 (1.0;3.0)	1.0 (0.0;2.0)	<0.001
Nocturia	2.0 (1.0;3.0)	1.5 (1.0–2.0)	0.5 (0.0;1.0)	<0.001
IIEF-5 score	14.5 (6.0–18.0)	17.5 (12.5–24.0)	22.5 (19.5–24.0)	<0.016
Total testosterone level (nmol/l)	8.3 (5.7–10.8)	13.05 (9.9–16.0)	17.05 (15.2–20.7)	<0.00001
Calculated free testosterone level (pmol/l)	149.5 (115.5–177.0)	244 (176–291)	382 (320.5–469.0)	<0.00001
SHBG (nmol/l)	34.3 (27.05–53.2)	38.8 (27.1–55.5)	30.2 (35.2–34.3)	0.76
Total PSA (pg/ml)	0.65 (0.4–1.21)	0.60 (0.4–1.25)	0.68 (0.4–1.3)	0.08

Table III.   Parameters during treatment in group 2 treated with TU injections. Results are expressed as median and quartile range.

	Before treatment	26 weeks of treatment	p
AMS score	40.0 (34.0–44.0)	24.0 (20.0–25.5)	0.004
IPSS score	12.0 (9.0–19.0)	6.5 (3.0–11.0)	0.004
Irritative symptoms (questions 2,4,7)	7.5 (6.0;11.0)	3.5 (2.0;7.0)	0.005
Obstructive symptoms (questions 1,3,5,6)	4.5 (3.0;7.0)	3.0 (1.0;4.0)	0.018
Nocturia	2.5 (1.0;4.0)	1.0 (0;2)	0.005
IIEF-5 score	12.0 (2.0–15.0)	19.5 (16.0–22.0)	0.004
Total testosterone level (nmol/l)	6.65 (5.6–9.4)	19.5 (16.7–21.7)	0.005
Calculated free testosterone level (pmol/l)	139.5 (115.0–161.0)	441.5 (387–524)	0.004
SHBG (nmol/l)	30.2 (25.6–40.9)	30.15 (25.6–33.8)	0.4
total PSA (pg/ml)	0.85 (0.5–1.5)	0.80 (0.5–1.4)	0.9